Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1016/j.numecd.2005.10.009. Epub 2006 Jan 18.
Affiliations
- PMID: 17126768
- DOI: 10.1016/j.numecd.2005.10.009
Randomized Controlled Trial
Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol
Leon A Simons et al. Nutr Metab Cardiovasc Dis. 2006 Dec.
Abstract
Background and aims: There is increasing interest in the use of natural therapies to reduce elevated low density lipoprotein (LDL) cholesterol. This study assessed the effects of PCC Lactobacillus fermentum on LDL cholesterol and other lipid fractions.
Methods and results: This was a single centre, double blind, placebo-controlled, parallel design trial in volunteers having total cholesterol > or =4 mmol/L. Subjects (n=46) were randomised to receive either Lactobacillus fermentum 2 capsules twice daily (each capsule containing 2 x 10(9) colony forming units) or matching placebo for a period of 10 weeks. Main outcome measures were percentage changes in LDL cholesterol and other lipids, changes in liver enzymes and other safety tests. Two subjects withdrew early in the study, 1 for personal reasons and 1 because of bowel discomfort. Three other subjects experienced some bowel discomfort but still completed the study. LDL cholesterol showed a modest downward trend on both Lactobacillus fermentum and placebo of 7.0% and 5.2% respectively. This trend did not reach statistical significance over time, nor was there a significant difference between the treatment arms. There were no significant changes over time or between treatments noted in total cholesterol, high density lipoprotein cholesterol or triglycerides. There were no significant changes in liver enzymes or other safety parameters with time or between treatments.
Conclusion: Lactobacillus fermentum did not appear to produce a major change in serum lipid fractions, but a small effect cannot be excluded.
Similar articles
- Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet.
Xie N, Cui Y, Yin YN, Zhao X, Yang JW, Wang ZG, Fu N, Tang Y, Wang XH, Liu XW, Wang CL, Lu FG. Xie N, et al. BMC Complement Altern Med. 2011 Jul 3;11:53. doi: 10.1186/1472-6882-11-53. BMC Complement Altern Med. 2011. PMID: 21722398 Free PMC article. - Lacticaseibacillus rhamnosus FM9 and Limosilactobacillus fermentum Y57 Are as Effective as Statins at Improving Blood Lipid Profile in High Cholesterol, High-Fat Diet Model in Male Wistar Rats.
Zafar H, Ain NU, Alshammari A, Alghamdi S, Raja H, Ali A, Siddique A, Tahir SD, Akbar S, Arif M, Alharbi M, Rahman A. Zafar H, et al. Nutrients. 2022 Apr 15;14(8):1654. doi: 10.3390/nu14081654. Nutrients. 2022. PMID: 35458216 Free PMC article. - Orally delivered microencapsulated live probiotic formulation lowers serum lipids in hypercholesterolemic hamsters.
Bhathena J, Martoni C, Kulamarva A, Urbanska AM, Malhotra M, Prakash S. Bhathena J, et al. J Med Food. 2009 Apr;12(2):310-9. doi: 10.1089/jmf.2008.0166. J Med Food. 2009. PMID: 19459731 - Lactobacillus fermentum FTDC 8312 combats hypercholesterolemia via alteration of gut microbiota.
Lye HS, Kato T, Low WY, Taylor TD, Prakash T, Lew LC, Ohno H, Liong MT. Lye HS, et al. J Biotechnol. 2017 Nov 20;262:75-83. doi: 10.1016/j.jbiotec.2017.09.007. Epub 2017 Sep 19. J Biotechnol. 2017. PMID: 28935567 - Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp shermanii JS administered in capsules is ineffective in lowering serum lipids.
Hatakka K, Mutanen M, Holma R, Saxelin M, Korpela R. Hatakka K, et al. J Am Coll Nutr. 2008 Aug;27(4):441-7. doi: 10.1080/07315724.2008.10719723. J Am Coll Nutr. 2008. PMID: 18978162 Clinical Trial.
Cited by
- Genomic and genetic characterization of the bile stress response of probiotic Lactobacillus reuteri ATCC 55730.
Whitehead K, Versalovic J, Roos S, Britton RA. Whitehead K, et al. Appl Environ Microbiol. 2008 Mar;74(6):1812-9. doi: 10.1128/AEM.02259-07. Epub 2008 Feb 1. Appl Environ Microbiol. 2008. PMID: 18245259 Free PMC article. - Biomedical applications of fermenticin HV6b isolated from Lactobacillus fermentum HV6b MTCC10770.
Kaur B, Balgir PP, Mittu B, Kumar B, Garg N. Kaur B, et al. Biomed Res Int. 2013;2013:168438. doi: 10.1155/2013/168438. Epub 2013 Jul 29. Biomed Res Int. 2013. PMID: 23984320 Free PMC article. - Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet.
Xie N, Cui Y, Yin YN, Zhao X, Yang JW, Wang ZG, Fu N, Tang Y, Wang XH, Liu XW, Wang CL, Lu FG. Xie N, et al. BMC Complement Altern Med. 2011 Jul 3;11:53. doi: 10.1186/1472-6882-11-53. BMC Complement Altern Med. 2011. PMID: 21722398 Free PMC article. - Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis.
Lee NY, Shin MJ, Youn GS, Yoon SJ, Choi YR, Kim HS, Gupta H, Han SH, Kim BK, Lee DY, Park TS, Sung H, Kim BY, Suk KT. Lee NY, et al. Clin Mol Hepatol. 2021 Jan;27(1):110-124. doi: 10.3350/cmh.2020.0125. Epub 2020 Dec 3. Clin Mol Hepatol. 2021. PMID: 33317254 Free PMC article. - Effects of Lactobacillus plantarum Q180 on Postprandial Lipid Levels and Intestinal Environment: A Double-Blind, Randomized, Placebo-Controlled, Parallel Trial.
Park YE, Kim MS, Shim KW, Kim YI, Chu J, Kim BK, Choi IS, Kim JY. Park YE, et al. Nutrients. 2020 Jan 19;12(1):255. doi: 10.3390/nu12010255. Nutrients. 2020. PMID: 31963808 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical